
Victoria, British Columbia
Vascularized 3D-bioprinted tissue.
3D-bioprinted human tissue with endothelial-lined microvasculature. Ready-to-use, perfusable models that help researchers study drug distribution, target engagement and potential liabilities in human tissue, starting with oncology.
The drugmaker problem
Animals and dishes fail the decision you actually have to make.
If you make a drug, the question is not whether a molecule looks interesting in a well. It is whether it reaches the tissue, hits the target, and what it does to human-like cells on the way.
A mouse is not a person. A two-dimensional assay has no vessels. Those are the two tools most programs still use to decide distribution, engagement, and early liabilities — and they are why good candidates die late, or bad ones go too far.
What they do
VoxCell BioInnovation.
VoxCell prints living human tissue in three dimensions, with blood-vessel-like channels lined by endothelial cells. Tumors first. The point is a piece of tissue that a drug can flow through the way it would in a person — not a dish, and not a mouse.
Pharma, biotech, CROs, and academic labs use those models to see how a candidate distributes, whether it hits the target, and what liabilities show up — without an animal model.
The models are ready-to-use, consumable, and perfusable. Breast and lung are among the first focuses.
Why you would use it
Study drug delivery and response in vascularized human tissue models.
- 01
Tissue penetration and distribution
Investigate how a drug candidate moves through perfusable, endothelial-lined channels and distributes within the surrounding three-dimensional tissue.
- 02
Tumor response
Assess treatment effects in a three-dimensional tumor microenvironment, using assays selected to measure cell viability, proliferation, or molecular responses.
- 03
Vascular and cellular toxicity
Evaluate treatment-related effects on endothelial cells and other cell populations within the model to investigate potential toxicity alongside antitumor activity.
- 04
Ready-to-use models
Perfusable tissue models supplied for laboratory testing, including breast and lung cancer models, without developing a tissue platform in-house.
Who it is for
Pharma, biotech, CROs, and academic researchers who need a human-relevant tissue decision without pretending a rodent is the patient.
Selected collaborations
Novel therapeutic. Commenced 2026.

Radiation, with the University of Victoria. Commenced 2025.
Radiation, with BC Cancer. Commenced 2025.

Breast cancer, with Inaphea. Commenced 2025.

Breast cancer, with ValiRx. Commenced 2025.

Commenced 2025.

Ocular. Commenced 2025.
Commenced 2025.

T cells, with NMI. Commenced 2024.
T cells, with TheryCell. Commenced 2024.
Neuro, with Open Culture Science. Commenced 2024.

Neuro, in collaboration with the University of California Santa Cruz. Commenced 2024.
On the board
RocketBio holds a board seat and supports business development.
Considering the next chapter for your business?
We welcome conversations with owners of established scientific tools and technology businesses who are considering a long-term partner.
